The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
10x Genomics, Inc. | CL A COM | 88025u109 | 20,059,518 | 359,554 | SH | SOLE | 20,059,518 | 0 | 0 | ||
Aadi Bioscience, Inc. | COM | 00032Q104 | 3,810,622 | 526,329 | SH | SOLE | 3,810,622 | 0 | 0 | ||
Adicet Bio, Inc. | COM | 007002108 | 3,340,800 | 580,000 | SH | SOLE | 3,340,800 | 0 | 0 | ||
Alpine Immune Sciences, Inc. | COM | 010392595 | 51,787,983 | 6,708,288 | SH | SOLE | 51,787,983 | 0 | 0 | ||
Apexigen, Inc. | COM | 03759B102 | 922,646 | 1,894,551 | SH | SOLE | 922,646 | 0 | 0 | ||
Arcus BioSciences, Inc. | COM | 03969f109 | 15,864,970 | 869,790 | SH | SOLE | 15,864,970 | 0 | 0 | ||
Argenx SE | SHS | 04016x101 | 10,219,497 | 27,429 | SH | SOLE | 10,219,497 | 0 | 0 | ||
AtriCure Inc. | COM | 04963C209 | 1,917,436 | 46,259 | SH | SOLE | 1,917,436 | 0 | 0 | ||
Aura Biosciences, Inc. | COM | 05153U107 | 2,722,130 | 293,333 | SH | SOLE | 2,722,130 | 0 | 0 | ||
BeyondSpring Inc. | SHS | G10830100 | 5,553,120 | 4,958,143 | SH | SOLE | 5,553,120 | 0 | 0 | ||
Cue Health Inc. | COM | 229790100 | 16,345,254 | 8,980,909 | SH | SOLE | 16,345,254 | 0 | 0 | ||
Equillium Inc. | COM | 29446K106 | 3,246,535 | 4,447,308 | SH | SOLE | 3,246,535 | 0 | 0 | ||
Horizon Therapeutics PLC | COM | G46188101 | 8,611,146 | 78,900 | SH | SOLE | 8,611,146 | 0 | 0 | ||
Illumnia, Inc. | COM | 452327109 | 18,803,760 | 80,859 | SH | SOLE | 18,803,760 | 0 | 0 | ||
Mersana Therapeutics, Inc. | COM | 59045L106 | 3,716,541 | 904,268 | SH | SOLE | 3,716,541 | 0 | 0 | ||
NeuBase Therapeutics, Inc. | COM | 64132K102 | 185,000 | 1,000,000 | SH | SOLE | 185,000 | 0 | 0 | ||
Owlet, Inc. | COM CL A | 69120X107 | 291,441 | 898,400 | SH | SOLE | 291,441 | 0 | 0 | ||
Pacific Biosciences of California, Inc. | COM | 69404D108 | 16,951,638 | 1,463,872 | SH | SOLE | 16,951,638 | 0 | 0 | ||
Prometheus Biosciences, Inc. | COM | 74349U108 | 16,098,000 | 150,000 | SH | SOLE | 16,098,000 | 0 | 0 | ||
Scynexis Inc. | COM NEW | 811292200 | 1,666,665 | 555,555 | SH | SOLE | 1,666,665 | 0 | 0 | ||
Seagen Inc. | COM | 812578102 | 4,659,645 | 23,014 | SH | SOLE | 4,659,645 | 0 | 0 | ||
GeneDx Holdings Corp. | COM CL A | 81663L101 | 1,247,909 | 3,418,929 | SH | SOLE | 1,247,909 | 0 | 0 | ||
Terns Pharmaceuticals, Inc. | COM | 880881107 | 8,457,134 | 714,285 | SH | SOLE | 8,457,134 | 0 | 0 | ||
Zentalis Pharmaceuticals Inc. | COM | 98943L107 | 31,382,828 | 1,824,583 | SH | SOLE | 31,382,828 | 0 | 0 |